Optimized immunohistochemistry in combination with image Analysis: a reliable alternative to quantitative ELISA determination of uPA and PAI-1 for routine risk group discrimination in breast cancer
Standard
Optimized immunohistochemistry in combination with image Analysis: a reliable alternative to quantitative ELISA determination of uPA and PAI-1 for routine risk group discrimination in breast cancer. / Lang, D S; Heilenkötter, U; Schumm, W; Behrens, O; Simon, R; Vollmer, E; Goldmann, T.
In: BREAST, Vol. 22, No. 5, 01.10.2013, p. 736-43.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Optimized immunohistochemistry in combination with image Analysis: a reliable alternative to quantitative ELISA determination of uPA and PAI-1 for routine risk group discrimination in breast cancer
AU - Lang, D S
AU - Heilenkötter, U
AU - Schumm, W
AU - Behrens, O
AU - Simon, R
AU - Vollmer, E
AU - Goldmann, T
N1 - Copyright © 2013 Elsevier Ltd. All rights reserved.
PY - 2013/10/1
Y1 - 2013/10/1
N2 - The determination of the invasion markers urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) has further improved the possibilities for individualized therapy of breast cancer. To date, quantitative measurement by ELISA, that needs large amounts of fresh, frozen material, is the only standardized procedure for diagnostic purposes. Therefore, the aim of this study was the establishment of a reliable alternative method based on immunohistochemistry (IHC) and image analysis requiring only small amounts of fixed tumor tissue. Protein expression of uPA and PAI-1 was analyzed in HOPE-fixed tumor samples using tissue microarrays (TMAs) and semiquantitative image analysis. The results of both methods were significantly correlated and risk assessment showed an overall concordance of 78% (83/107; high- and low-risk) and of 94% (74/79) regarding only high-risk patients. The data demonstrate that optimized IHC in combination with image analysis can provide adequate clinical significance compared to ELISA-derived determination of uPA and PAI-1.
AB - The determination of the invasion markers urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) has further improved the possibilities for individualized therapy of breast cancer. To date, quantitative measurement by ELISA, that needs large amounts of fresh, frozen material, is the only standardized procedure for diagnostic purposes. Therefore, the aim of this study was the establishment of a reliable alternative method based on immunohistochemistry (IHC) and image analysis requiring only small amounts of fixed tumor tissue. Protein expression of uPA and PAI-1 was analyzed in HOPE-fixed tumor samples using tissue microarrays (TMAs) and semiquantitative image analysis. The results of both methods were significantly correlated and risk assessment showed an overall concordance of 78% (83/107; high- and low-risk) and of 94% (74/79) regarding only high-risk patients. The data demonstrate that optimized IHC in combination with image analysis can provide adequate clinical significance compared to ELISA-derived determination of uPA and PAI-1.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Breast Neoplasms
KW - Carcinoma, Ductal, Breast
KW - Carcinoma, Lobular
KW - Enzyme-Linked Immunosorbent Assay
KW - Female
KW - Humans
KW - Image Enhancement
KW - Immunohistochemistry
KW - Middle Aged
KW - Plasminogen Activator Inhibitor 1
KW - Risk Assessment
KW - Tissue Array Analysis
KW - Tumor Markers, Biological
KW - Urokinase-Type Plasminogen Activator
U2 - 10.1016/j.breast.2012.12.011
DO - 10.1016/j.breast.2012.12.011
M3 - SCORING: Journal article
C2 - 23332148
VL - 22
SP - 736
EP - 743
JO - BREAST
JF - BREAST
SN - 0960-9776
IS - 5
ER -
